Literature DB >> 823030

Comparison of the pharmacokinetics of glipizide and glibenclamide in man.

L Balant, J Fabre, G R Zahnd.   

Abstract

Four subjects received 5 mg 14C-glipizide orally, 3 subjects 1 mg intravenously and 2 subjects 5 mg 14C-glibenclamide orally. Plasma levels of radioactivity, and urinary and faecal excretion were measured. For both drugs the disappearance of radioactivity from plasma followed complex kinetics and the apparent half-lives increased steadily with time. The two sulfonylureas were extensively metabolized and were excreted in the urine as hydroxylated or conjugated metabolites. The effects of both drugs on blood glucose and immunoreactive insulin were comparable. The findings are compared with other published results.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 823030     DOI: 10.1007/BF00616416

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  [An automatic micro-method for the quantitative analysis of aldohexoses in biological fluids by o-toluidine].

Authors:  R ZENDER
Journal:  Clin Chim Acta       Date:  1963-05       Impact factor: 3.786

2.  Immunoassay of insulin with insulin-antibody precipitate.

Authors:  C N HALES; P J RANDLE
Journal:  Biochem J       Date:  1963-07       Impact factor: 3.857

3.  Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.

Authors:  L M Fuccella; V Tamassia; G Valzelli
Journal:  J Clin Pharmacol New Drugs       Date:  1973 Feb-Mar

Review 4.  Pharmacokinetic aspects of drug metabolism.

Authors:  M Gibaldi
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

5.  [Resorption, excretion and metabolism after intravenous and oral administration of HB 419-14C in man].

Authors:  W Rupp; O Christ; W Heptner
Journal:  Arzneimittelforschung       Date:  1969-08

6.  [Glucose and HB 419-concentration in blood as well as HB 419-excretion in urine after single oral application of HB 419-14C].

Authors:  H A Schmidt; P Petrides
Journal:  Arzneimittelforschung       Date:  1969-08

7.  [The behavior of doxycycline in man].

Authors:  J Fabre; J P Kunz; C Virieux; J L Laurencet; J S Pitton
Journal:  Chemotherapia (Basel)       Date:  1968

8.  [Studies on the bioavailability of glibenclamide].

Authors:  W Rupp; O Christ; W Fülberth
Journal:  Arzneimittelforschung       Date:  1972-02

9.  [Potentiation of the hypoglycemic effect of sulfonylurea derivatives by drugs. II. Pharmacokinetics and metabolism of glibenclamide (HB 419) in presence of phenylbutazone].

Authors:  E Schulz; K Koch; F H Schmidt
Journal:  Eur J Clin Pharmacol       Date:  1971-12       Impact factor: 2.953

10.  Influence of repetitive dosing of tetracyclines on biologic half-life in serum.

Authors:  J T Doluisio; L W Dittert
Journal:  Clin Pharmacol Ther       Date:  1969 Sep-Oct       Impact factor: 6.875

View more
  20 in total

1.  Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.

Authors:  S W Coppack; A F Lant; C S McIntosh; A V Rodgers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

2.  The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.

Authors:  Bo Tan; Yi-Fan Zhang; Xiao-Yan Chen; Xiao-Hua Zhao; Guo-Xin Li; Da-Fang Zhong
Journal:  Eur J Clin Pharmacol       Date:  2009-10-22       Impact factor: 2.953

3.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

4.  Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide.

Authors:  J B Chalk; M Patterson; M T Smith; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

6.  Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone.

Authors:  Richard S Geary; JoAnn D Bradley; Tanya Watanabe; Younggil Kwon; Mark Wedel; Jan J van Lier; André A VanVliet
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Behaviour of glibenclamide on repeated administration to diabetic patients.

Authors:  L Balant; G R Zahnd; F Weber; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

8.  Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins.

Authors:  H Schelleman; X Han; C M Brensinger; S K Quinney; W B Bilker; D A Flockhart; L Li; Sean Hennessy
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

9.  Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics.

Authors:  E Wåhlin-Boll; L O Almér; A Melander
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

10.  Glibenclamide-associated hypoglycaemia: a report on 57 cases.

Authors:  K Asplund; B E Wiholm; F Lithner
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.